All COVID-19 updates and resources can be found on the CF Canada website.

Skip To Content
Volunteer Advocate
cf insights cf insights

ADVOCACY UPDATE & LATEST NEWS FROM CYSTIC FIBROSIS CANADA: JANUARY 8

CFCANTWAIT: ADVOCACY UPDATES

Rapid Review of Trikafta In Progress

Trikafta has been formally accepted for review by Health Canada and their website has been updated to reflect this. This means the 180 day deadline for a fast tracked Health Canada review has begun, though this timeline could change if Health Canada needs to request additional information. It’s listed on the Health Canada website by the medicinal ingredients elexacaftor, ivacaftor and tezacaftor.

CADTH Review of Trikafta Underway: Tell us What you Think

The Canadian Agency for Drugs and Technologies in Health (CADTH) is currenting reviewing Trikafta. CADTH conducts cost-effectiveness reviews on medicines. Provincial governments use the results of these reviews to inform their decisions on whether or not to publicly reimburse medicines. Increasingly, private insurers are also relying on CADTH reviews to inform their drug reimbursement decision-making.

As part of this review and that by the Institut national d’excellence en santé et en services sociaux (INESSS), Cystic Fibrosis Canada will provide a patient group submission, which is due on February 12, 2021 and February 24. To ensure that patient and caregiver voices are heard, we will be conducting a community survey from January 15-25, 2021. Please stay tuned for more information on the survey!

PMPRB Changes Delayed Further

Implementation of the Patented Medicines Regulations and final Patented Medicine Prices Review Board (PMPRB) Guidelines has been delayed for 6 months to July 1, 2021. Health Canada has stated the primary reason for the delay are the challenges posed by COVID-19.

Additionally, Health Canada stated that the delay will provide drug manufacturers with additional time to prepare for the new reporting obligations and to familiarize themselves with the PMPRB’s final Guidelines.

While Cystic Fibrosis Canada does not anticipate that this delay will impact the rapid speed at which Trikafta is working its way through our drug regulatory and review processes, we are seeking clarification on the treatment of Trikafta from the manufacturer and the PMPRB.

CF Canada Calls for Early Access to COVID-19 Vaccines

Before the holidays, Cystic Fibrosis Canada sent a letter to all provincial Health ministers, stating that vulnerable groups with pre-existing conditions like those living with cystic fibrosis deserve early protection. We continue to advocate for priority access to the vaccine for people living with cystic fibrosis.

Our COVID-19 resource page will continue to provide timely updates on COVID-19 news, including access to vaccines.


Further News

Year End

That’s a wrap! 2020 has been a year unlike any other and during the holiday season, 1,822 donors chose to give in support of those living with cystic fibrosis. They have helped raise an astounding $379,453.40! With our generous match, the total raised is $529,453.40 to give more special moments for Canadians with CF – like Megan, Hailey, and William. Thank you, a thousand times!

Your holiday gift will help us push further so that people with cystic fibrosis have longer, healthier lives. Thank you for your incredible support in 2020.


In the News


Did you miss?: